Our data show that Givinostat improves the functional activities and modifies the histological parameters in a dose-dependent way regardless of the Ltbp4 haplotype; indeed, Givinostat is effective in both the mdx (DMD mild phenotype) and in D2.B10 (DMD severe phenotype) murine models. Here, LTBP4 is linked to Duchenne muscular dystrophy.